Which chronic myeloproliferative disorder is treated with Imatinib mesylate (Gleevec), a drug that inhibits tyrosine kinase?

Question

Quizplus · Accepted Answer

Imatinib mesylate (Gleevec) is a drug that specifically inhibits the tyrosine kinase activity of the BCR-ABL fusion protein, which is present in most cases of chronic myelogenous leukemia (CML). Therefore, it is a targeted therapy for the treatment of CML. It is not used to treat polycythemia vera, essential thrombocythemia, or primary myelofibrosis.

Which Chronic Myeloproliferative Disorder Is Treated with Imatinib Mesylate (Gleevec)